Anika reports inducement grants
Anika Therapeutics, Inc. announced that it granted 3,138 restricted stock units (RSUs) to a newly hired non-executive employee on April 1, 2026. These RSUs, made as a material inducement for employment, will vest in three equal installments over three years, subject to continuous service. The grant was made under the Anika Therapeutics, Inc. 2021 Inducement Plan and did not require stockholder approval.
Anika Reports Inducement Grants Under Nasdaq Listing Rule
Anika Therapeutics, Inc. announced a grant of restricted stock units (RSUs) covering 3,138 shares to a new non-executive employee on April 1, 2026. This move highlights Anika's strategy of using equity-based compensation to attract and retain talent in the competitive biotech industry, with the RSUs vesting in three equal annual installments. Such inducement grants are permitted under Nasdaq rules to help public companies offer competitive compensation packages.
New Anika employee gets 3,138 stock units vesting over 3 years
Anika Therapeutics announced it granted 3,138 restricted stock units (RSUs) to a new non-executive employee on April 1, 2026, as an inducement under Nasdaq Listing Rule 5635(c)(4). These RSUs will vest in three equal annual installments, subject to continued service. This grant aligns with Anika's strategy of using equity compensation for talent retention and motivation, following recent positive financial performance and leadership updates.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. announced inducement grants of restricted stock units (RSUs) covering 3,138 shares of common stock to a newly hired non-executive employee on April 1, 2026. These grants were made under the company's 2021 Inducement Plan, as amended, following approval by the compensation committee and in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in three equal installments over three years, contingent on continuous service, and were not subject to stockholder approval.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics, Inc. announced inducement grants of restricted stock units (RSUs) covering 3,138 shares to a new non-executive employee on April 1, 2026. These RSUs will vest in three equal annual installments and were granted under the company's 2021 Inducement Plan, which was not subject to stockholder approval, in accordance with Nasdaq Listing Rule 5635(c)(4). This grant serves as a material inducement for the employee's acceptance of employment.
Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200 Day Moving Average - What's Next?
Anika Therapeutics (NASDAQ:ANIK) saw its share price move above its 200-day moving average, reaching $14.98 with a volume of 187,844 shares. Analyst sentiment is mixed but leans positive, with Barrington Research raising its price target to $17 and a consensus target price of $19. Financially, Anika Therapeutics beat Q4 earnings estimates but still posted a negative net margin and forecasted a full-year EPS of -0.84, while institutional investors own a significant 91.53% of the company.
The Technical Signals Behind (ANIK) That Institutions Follow
This article provides a technical analysis of Anika Therapeutics Inc. (NASDAQ: ANIK) as of March 28, 2026, outlining institutional trading signals and strategies. It highlights a potential shift in positive near-term sentiment while indicating broader weak alignment and elevated downside risk. The analysis includes AI-generated signals across multiple timeframes, offering position trading, momentum breakout, and risk hedging strategies for investors.
Vanguard disaggregates holdings; ANIK shows 0% after realignment (NYSE: ANIK)
Vanguard Group has filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Anika Therapeutics (ANIK) shares following an internal realignment. This change is due to certain Vanguard subsidiaries beginning to report their holdings separately, in accordance with SEC Release No. 34-39538, and does not indicate a market transaction or sale of shares. The filing clarifies a reporting structure adjustment rather than a change in investment strategy or a divestment.
Anika Therapeutics (NASDAQ:ANIK) Share Price Crosses Above 200-Day Moving Average - Time to Sell?
Anika Therapeutics (NASDAQ:ANIK) shares recently crossed above their 200-day moving average, trading at $14.28 with a 200-day MA of $10.20. Analyst opinions are mixed, resulting in a "Moderate Buy" consensus with an average target price of $19.00. Despite beating Q4 earnings estimates, the company remains unprofitable with negative net margin and return on equity, and analysts project a negative EPS for the current year.
Anika Therapeutics (ANIK) SVP Ian McLeod granted RSUs and PPSARs
Anika Therapeutics' SVP, CAO & Treasurer, Ian McLeod, was granted new equity awards on March 19, 2026, including two Restricted Stock Unit (RSU) awards totaling 24,291 units and 17,663 Premium Priced Stock Appreciation Rights (PPSARs) with an exercise price of $15.60. These awards are subject to multi-year vesting schedules, aligning his compensation with the company's long-term performance. The grants do not involve any open-market transactions or derivative exercises.
Anika Therapeutics (Nasdaq:ANIK) - Stock Analysis
This Simply Wall Street analysis of Anika Therapeutics (ANIK) describes the company as a joint preservation company trading below its estimated fair value. It provides an overview of the company's financials, including a market cap of US$185.6m and recent revenue and earnings figures, noting risks such as declining revenue and earnings growth. The report also highlights recent news, price performance, and analyst coverage, emphasizing the long-term tailwinds from aging demographics and demand for orthopedic solutions.
If You Invested $1,000 in Anika Therapeutics Inc (ANIK)
This article analyzes the historical performance of Anika Therapeutics Inc (ANIK) stock, detailing how a $1,000 investment would have fared over 1, 5, and 10 years, showing significant losses compared to the S&P 500. It also provides a comprehensive overview of the company, including its business focus on early intervention orthopedics and joint preservation, key product families like Cingal and Hyalofast, channels, and strategic positioning. The article further touches upon the company's research, clinical programs, regulatory pathways, corporate governance, and leadership.
ANIK Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial analysis of Anika Therapeutics Inc (ANIK), detailing its revenue breakdown, profitability margins, and a comparison with competitors. ANIK generates most of its revenue from OEM Channel and exhibits a gross margin of 62.65%. The analysis benchmarks ANIK's financial performance against industry leaders like ELMD and SNWV to offer insight into its market position.
Regenerative Medicine Market Is Going to Boom | Anika Therapeutics, Inc. and Arthrex
The Regenerative Medicine market is predicted to grow significantly, from an estimated US$ 7,090.1 Mn in 2025 to US$ 14,074.3 Mn by 2032, exhibiting a CAGR of 10.3%. A new report by Coherent Market Insights provides an in-depth analysis of market trends, drivers, challenges, and competitive strategies, offering insights for strategic investments and informed business decisions. Key players highlighted include Anika Therapeutics, Arthrex, Baxter International, and Medtronic.
Anika Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout
Anika Therapeutics, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has formed a Golden Cross, often signaling a bullish trend. Despite a challenging one-year performance, the stock has seen a significant one-day rise of 11.96% and a 34.71% surge over the past week, with year-to-date performance at 49.01%. Mixed technical indicators suggest varying investor sentiment, but the Golden Cross implies a potential shift towards increased buying interest.
Anika Therapeutics (NASDAQ: ANIK) CEO adds shares via RSU vesting and award
Anika Therapeutics' President and CEO, Stephen D. Griffin, engaged in equity compensation activities related to restricted stock unit vesting. On March 14, 2026, he exercised 12,824 RSUs, acquired 6,412 shares as a grant, and had 5,944 shares withheld for tax obligations. Following these transactions, Griffin directly holds 23,963 shares of Anika Therapeutics common stock.
Anika Therapeutics (ANIK) director vests RSUs, withholds shares for taxes
Anika Therapeutics director Cheryl R. Blanchard vested RSUs and performance-based RSUs on March 14 and 15, 2026, which converted into common shares. The company withheld a total of 26,832 shares at $14.20 per share to cover tax obligations, rather than Blanchard selling shares in the open market. Following these transactions, Blanchard directly holds 258,788 common shares and indirectly holds 11,742 shares through a revocable trust.
Anika Therapeutics (NASDAQ: ANIK) SVP gains shares via RSUs, covers taxes with stock
Anika Therapeutics (NASDAQ: ANIK) SVP, CAO & Treasurer Ian McLeod reported significant stock activity related to compensation. He acquired shares through RSU exercises and grants on March 14 and March 15, 2026. The company retained a portion of these shares to cover tax withholding obligations. Following these transactions, McLeod directly holds 24,107 shares of Anika common stock and 2,659 restricted stock units.
Precision Trading with Anika Therapeutics Inc. (ANIK) Risk Zones
This article provides a detailed analysis of Anika Therapeutics Inc. (ANIK) using AI-generated signals for precision trading. It highlights the current weak sentiment for ANIK, suggesting potential near-term weakness that could test mid-term strength within a broader long-term weak bias. The analysis includes specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses, alongside multi-timeframe signal analysis for support and resistance levels.
Anika Therapeutics (NASDAQ:ANIK) Shares Pass Above 200-Day Moving Average - What's Next?
Anika Therapeutics (NASDAQ:ANIK) shares recently surged above their 200-day moving average, signaling a technical breakout despite mixed analyst ratings. The company beat recent quarterly earnings estimates but maintains a negative net margin and is projected to report a negative full-year EPS. Institutional investors have been actively modifying their holdings in Anika Therapeutics.
Anika Therapeutics falls after its completes divestiture of Parcus Medical business
Anika Therapeutics' shares fell 2.7% after the company announced it completed the divestiture of its Parcus Medical business to Medacta Group. This move allows Anika to focus on its core hyaluronic acid technology and expand its regenerative solutions portfolio. The company had reported its plan to divest Parcus Medical in October 2024.
Anika Therapeutics (ANIK) EVP’s RSUs Vest with Shares Withheld for Taxes
Anika Therapeutics EVP and General Counsel David Colleran had 5,465 restricted stock units (RSUs) vest on March 9, 2026, from a grant made in 2023. These RSUs converted into an equal number of common shares. To cover tax withholding obligations, 1,919 shares were retained by the company at $14.96 per share, rather than being sold on the market. Afterward, Colleran directly holds 53,100 shares of Anika Therapeutics common stock.
Anika Therapeutics (ANIK) director nets RSU shares after tax withholding
Anika Therapeutics director Cheryl R. Blanchard reported the vesting of 20,001 restricted stock units (RSUs) into common shares, marking the third and final installment of an award granted on March 9, 2023. Of these, 5,871 shares were withheld for tax obligations at $14.96 per share, resulting in a net increase of 14,130 shares for Blanchard. Following these transactions, she holds 211,450 shares directly and 11,742 shares indirectly through a revocable trust.
Anika Therapeutics Earnings Call Signals Cautious Rebound
Anika Therapeutics' Q4 earnings call revealed a mixed outlook, with strong commercial channel sales and improved profitability metrics contrasting with flat overall revenue and setbacks in the OEM channel and regulatory pipeline. The company is focusing on sustaining commercial growth and implementing cost actions, but faces challenges with regulatory uncertainties and pricing pressures. Investors will monitor their ability to convert early profitability gains into sustained earnings.
Anika Therapeutics (NASDAQ:ANIK) Rating Increased to Strong-Buy at Wall Street Zen
Wall Street Zen has upgraded Anika Therapeutics (NASDAQ:ANIK) from a "buy" to a "strong-buy" rating. This upgrade comes as the company continues to report financial results, with recent earnings beating analyst estimates. Anika Therapeutics, a life sciences company focused on hyaluronic acid-based therapeutic products, has a current average price target of $19.00 and a "Moderate Buy" consensus rating from analysts.
Trigran Investments Inc. Sells 415,296 Shares of Anika Therapeutics Inc. $ANIK
Trigran Investments Inc. reduced its stake in Anika Therapeutics Inc. (NASDAQ:ANIK) by 20.4% in the third quarter, selling 415,296 shares and now owning 1,621,215 shares valued at $15.2 million. Despite the sell-off, Anika Therapeutics exceeded earnings estimates with $0.31 EPS and $30.62 million in revenue. Institutional ownership of Anika Therapeutics remains high at 91.53%, and analysts currently rate the stock as a "Moderate Buy" with a consensus price target of $19.00.
Technical Reactions to ANIK Trends in Macro Strategies
This article provides a technical analysis of Anika Therapeutics Inc. (NASDAQ: ANIK), highlighting near and mid-term positive sentiment but a weak long-term outlook with elevated downside risk. It presents three AI-generated trading strategies—position, momentum breakout, and risk hedging—along with multi-timeframe signal analysis indicating support and resistance levels. The report emphasizes the use of AI models for optimizing position sizing and minimizing drawdown risk.
Anika Therapeutics 2025 10-K: Revenue $112.8M, Diluted Loss per Share $(0.70)
Anika Therapeutics reported 2025 full-year revenue of $112.8 million and a diluted loss of $(0.70) per share, despite a 6% revenue decline due to lower OEM pricing and volumes. The company's net loss improved to $(10.9) million from $(56.4) million in 2024, primarily due to reduced losses from discontinued operations. Strategic divestitures of Arthrosurface and Parcus were completed to focus on osteoarthritis pain management and regenerative solutions.
ANIK | Anika Therapeutics Inc Financials - Income Statement
This page provides financial information for Anika Therapeutics Inc (ANIK), focusing on its income statement and other critical company data. It includes details on congressional trading activity, insider transactions, institutional holdings, revenue breakdowns, patents, and government contracts. The article also touches on analyst ratings, stock forecasts, top shareholders, and the company's Smart Score, along with a description of Anika Therapeutics Inc's business.
Barrington Research Forecasts Strong Price Appreciation for Anika Therapeutics (NASDAQ:ANIK) Stock
Barrington Research has raised its price target for Anika Therapeutics (NASDAQ:ANIK) to $17 from $16, maintaining an "outperform" rating and suggesting an 18% upside. This follows Anika's strong Q4 earnings beat, where the company exceeded EPS and revenue estimates, generating significant operating and free cash flow, and issued positive 2026 revenue guidance. However, regulatory risk from an FDA response on its Hyalofast® PMA remains a potential uncertainty.
Anika Therapeutics Q4 Profit Challenges Narratives Around Ongoing Losses For ANIK Investors
Anika Therapeutics (ANIK) reported Q4 2025 revenue of US$30.6 million and a positive EPS of US$0.13, contradicting narratives of ongoing losses, despite a trailing 12-month net loss of US$10.0 million. The company's revenue growth of 5.5% trails the broader US market, but its valuation appears low compared to peers, trading at a P/S of 1.8x against an indicated DCF fair value of US$16.25. Investors are weighing the recent profitable quarter against the full-year loss and modest revenue growth, while considering potential future catalysts like product approvals.
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2025 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK) reported Q4 2025 earnings, beating expectations with a reported EPS of $0.1228 against an expected $0.02. The company highlighted strong commercial channel growth, particularly in international OA pain management and Integrity product adoption, while OEM revenue declined due to pricing challenges. Anika also outlined its strategic priorities for 2026, focusing on accelerating revenue growth, advancing its HA-based innovation pipeline, and improving operational execution to drive profitability and cash generation.
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika Therapeutics (ANIK) reported Q4 earnings of $0.31 per share, significantly surpassing the Zacks Consensus Estimate of $0.02. The company also beat revenue estimates, reporting $30.62 million against an expectation of $30.6 million. Despite outperforming the market year-to-date, Anika currently holds a Zacks Rank #3 (Hold).
Anika Therapeutics extends transition agreement with Paul Colleran as EVP, General Counsel
Anika Therapeutics (ANIK) has extended its transition agreement with Paul Colleran, retaining him as Executive Vice President, General Counsel, and Corporate Secretary until an anticipated separation date of May 1, 2026. This agreement outlines his continued services, compensation, benefits, and equity award vesting during the transition period. The arrangement is detailed in a Transitional Services and General Release of Claims Agreement dated February 26, 2026.
Anika Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:ANIK) 2026-02-27
SA Transcripts published Anika Therapeutics, Inc.'s Q4 2025 earnings call presentation. The company reported EPS of $0.31, beating estimates by $0.29, and revenue of $30.62M, exceeding expectations by $1.74M with a slight year-over-year increase. This article provides the slide deck in conjunction with the earnings call.
Anika (NASDAQ: ANIK) lifts margins as 2025 loss narrows sharply
Anika Therapeutics reported flat Q4 2025 revenue at $30.6 million but significantly improved its gross margin to 63%, driven by strong commercial channel growth. For the full year 2025, revenue was down 6% to $112.8 million, yet the company sharply narrowed its net loss to $10.9 million from $56.4 million in 2024, demonstrating improved profitability and positive cash flow. Anika also provided 2026 guidance, expecting total revenue between $114 million and $122.5 million, and continued progress on key pipeline assets and a share repurchase program.
Anika Therapeutics Inc (ANIK) Q4 2025 Earnings Call Highlights: Strong International Growth and Margin Improvements Amid Challenges
Anika Therapeutics Inc (ANIK) reported robust Q4 2025 results, demonstrating 22% commercial channel revenue growth driven by international strength and its Integrity product. The company improved its GAAP gross margin to 63% for the quarter and generated $11.2 million in operating cash flow for the year, up from 2024. Despite these positive trends, Anika faced challenges including a decline in OEM revenue due to a difficult U.S. OA pain management pricing environment and regulatory hurdles with an FDA deficiency letter for Hyalofast.
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Anika Therapeutics, Inc. reported its fourth quarter and full year 2025 financial results, with fourth-quarter revenue flat at $30.6 million and full-year revenue at $112.8 million, a 6% decrease from 2024. The Commercial Channel saw significant growth (22% in Q4, 15% for the year), driven by international sales and the Integrity Implant System, while the OEM Channel declined. The company provided 2026 revenue guidance between $114 million and $122.5 million and is continuing its $15 million share repurchase program.
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika Therapeutics (ANIK) reported strong Q4 results, surpassing Zacks Consensus Estimates for both earnings and revenue. The company posted earnings of $0.31 per share against an expected $0.02, and revenues of $30.62 million, exceeding the $28.88 million estimate. Despite the positive results and recent stock performance, ANIK currently holds a Zacks Rank #3 (Hold).
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Anika Therapeutics Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company met its 2025 revenue and exceeded adjusted EBITDA targets, reaffirming its 2026 revenue and setting an adjusted EBITDA target. Key highlights include 22% and 15% growth in the Commercial Channel for the fourth quarter and full year respectively, $11.2 million in operating cash flow, and $4.4 million in free cash flow for the full year.
Insights into Anika Therapeutics Q4 Earnings
Anika Therapeutics (NASDAQ: ANIK) announced its Q4 earnings on February 26, 2026, beating estimated EPS by 616.67% with a reported $0.31 per share versus an estimate of $-0.06. Revenue also saw a $13 thousand increase compared to the same period last year. This positive earnings surprise follows previous quarters where the company demonstrated mixed results but indicates strong performance in the most recent quarter.
Anika Therapeutics Q4 Earnings Call Highlights
Anika Therapeutics reported mixed results for Q4 and full-year 2025, with flat Q4 revenue of $30.6M driven by commercial channel growth offsetting an OEM decline, and a 6% full-year revenue decrease to $112.8M. The company guided for modest 2026 revenue growth of 1% to 9% ($114M–$122.5M) and 5%–10% adjusted EBITDA, focusing on commercial channel expansion, pipeline advancement for its HA-based products like Integrity and Cingal, and operational improvements to boost profitability and cash flow. Anika also highlighted progress in its pipeline with Integrity's increased sales and Cingal surpassing one million injections, despite regulatory hurdles for Hyalofast.
Trading the Move, Not the Narrative: (ANIK) Edition
This article provides an AI-driven analysis of Anika Therapeutics Inc. (NASDAQ: ANIK), highlighting strong near and mid-term sentiment but a weak long-term outlook. It details specific trading strategies—Position, Momentum Breakout, and Risk Hedging—with entry, target, and stop-loss levels, and offers multi-timeframe signal analysis for various horizons. The article emphasizes utilizing AI for predictive trading and risk management for ANIK.
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced that its President and CEO, Steve Griffin, will present at the Canaccord Genuity 2026 Musculoskeletal Conference on March 2, 2026. Management will also hold one-on-one investor meetings at the event. The presentation will be webcast live on Anika's investor relations website.
Anika Therapeutics (ANIK) Expected to Announce Quarterly Earnings on Thursday
Anika Therapeutics (ANIK) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts projecting earnings of $0.02 per share and revenue of $28.875 million. The stock currently trades around $10.52, and institutional investors hold a significant 91.53% of its shares. Analyst consensus rates ANIK as a "Moderate Buy" with a target price of $18.50.
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will issue its fourth quarter and year-end 2025 financial results on Thursday, February 26, 2026, before market open. A conference call will follow at 8:30 a.m. ET to discuss the results and business highlights, with access details provided for both dial-in and webcast. The announcement emphasizes Anika's focus on joint preservation in early intervention orthopedics.
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its fourth-quarter and year-end 2025 financial results on Thursday, February 26, 2026, before market open. This will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or a live audio webcast on Anika's website.
(ANIK) Volatility Zones as Tactical Triggers
This article provides a detailed analysis of Anika Therapeutics Inc. (NASDAQ: ANIK) using AI-generated volatility zones and tactical triggers for trading strategies. It identifies near-term weak sentiment, mid-term strength, and long-term weak bias, offering specific entry, target, and stop-loss levels for position trading, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200-Day Moving Average - What's Next?
Anika Therapeutics (NASDAQ:ANIK) stock price has moved above its 200-day moving average of $9.37, trading as high as $10.62. The company has a market cap of $148.97 million, and analyst ratings are mixed but lean towards a "Moderate Buy" with a consensus price target of $18.50. Institutional investors own a significant portion of the company's stock, with hedge funds increasing their positions in the last quarter.
Positive week for Anika Therapeutics, Inc. (NASDAQ:ANIK) institutional investors who lost 41% over the past year
Institutional investors in Anika Therapeutics, Inc. (NASDAQ:ANIK) experienced a positive week with a 17% share price increase, partially recovering from a 41% loss over the past year. Institutions hold a significant 65% ownership, with the top 10 shareholders controlling 51% of the company. BlackRock, Inc. is the largest shareholder at 12%, while insiders own shares valued at US$5.9 million.
